+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture, Type of Media, Scale of Operation, Type of End-User, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

  • ID: 5559354
  • Report
  • March 2022
  • Region: Global
  • 180 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 2BScientific
  • Bio Farma
  • Cytiva
  • Intervet
  • MolecuVax
  • Scandinavian Biopharma
Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.

Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.


Scope of the Report



The “Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. 


Amongst other elements, the report features:


  • A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing). 
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
  • An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
  • An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
  • An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
  • An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
  • Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. 
  • An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.



One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the key players engaged in the development of viral vaccine cell culture media?
  • Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • What is the relative competitiveness of different viral vaccine cell culture media?
  • Who are the most likely partners for vaccine cell culture media developers?
  • What are the key challenges currently faced by stakeholders in this industry?
  • What are the anticipated future trends related to viral vaccine cell culture media developers?
  • How is the current and future market opportunity likely to be distributed across key market segments? 
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 2BScientific
  • Bio Farma
  • Cytiva
  • Intervet
  • MolecuVax
  • Scandinavian Biopharma

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Viral Vaccine
3.2.1. Vaccine Components
3.2.2. Historical Evolution
3.2.3. Viral Vaccine Development
3.3. Type of Viral Vaccine
3.3.1. Whole Virus
3.3.2. Protein Subunit
3.3.3. Nucleic Acid
3.3.4 Viral Vector
3.4. Type of Cell Culture
3.5. Type of Cell Culture Media
3.6. Advantages of Cell Culture Media
3.7. Limitations Associated with Cell Culture Media
3.8. Conclusion
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
4.2.1. Analysis by Type of Vaccine
4.2.2. Analysis by Type of Cell Culture
4.2.3. Analysis by Type of Cell Culture Media
4.2.4. Analysis by Type of Cell Culture and Media
4.2.5. Analysis by Type of Cell Line
4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
4.2.7. Analysis by Media Formulation
4.2.8. Analysis by Application Area
4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Products
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Players based in North America
5.2.1. Creative Biolabs
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Portfolio
5.2.1.4. Future Outlook
5.2.2. Jianshun Biosciences
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Portfolio
5.2.2.4. Future Outlook
5.2.3. Thermo Fisher Scientific
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Portfolio
5.2.3.4. Future Outlook
5.3. Players based in Europe
5.3.1. Merck
5.3.1.1. Company Overview
5.3.1.2. Financial Information
5.3.1.3. Product Portfolio
5.3.1.4. Future Outlook
5.3.2. Sartorius
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Product Portfolio
5.3.2.4. Future Outlook
5.3.3. Xell
5.3.3.1. Company Overview
5.3.3.2. Financial Information
5.3.3.3. Product Portfolio
5.3.3.4. Future Outlook
5.4. Players based in Asia-Pacific
5.4.1. ATZ labs
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Product Portfolio
5.4.1.4. Future Outlook
5.4.2. OPM Biosciences
5.4.2.1. Company Overview
5.4.2.2. Financial Information
5.4.2.3. Product Portfolio
5.4.2.4. Future Outlook
6. RECENT DEVELOPMENTS AND INITIATIVES
6.1. Chapter Overview
6.2. Partnership Models
6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.2.1. Analysis by Year and Type of Partnership
6.3.2.2. Analysis by Type of Partnership and Company Size
6.3.3. Most Active Players: Analysis by Number of Partnerships
6.3.4. Regional Analysis
6.3.4.1. Intercontinental and Intracontinental Agreements
6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
6.3.6. Analysis by Type of Acquisition
6.3.7. Analysis by Key Value Drivers
6.3.8. Analysis by Year of Acquisition and Key Value Drivers
6.4. Viral Vaccine Cell Culture Media: Recent Expansions
7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.4. Product Competitiveness: Adherent Cell Culture Media
8.5. Product Competitiveness: Suspension Cell Culture Media
9. BRAND POSITIONING
9.1. Chapter Overview
9.2. Key Parameters and Methodology
9.3. Brand Positioning Matrix: Cytiva
9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
9.5. Brand Positioning Matrix: Lonza
9.6. Brand Positioning Matrix: Merck
9.7. Brand Positioning Matrix: Sartorius
9.8. Brand Positioning Matrix: Thermo Fisher Scientific
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Viral Vaccine Cell Culture Media: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Granted Patents
10.3.4. Year-wise Trend of Filed Patent Applications
10.3.5. Analysis by Issuing Authority
10.3.6. Analysis by Patent Focus
10.3.7. Analysis by Patent Age
10.3.8. Analysis by CPC Symbols
10.3.9. Analysis by Type of Applicant
10.3.10. Leading Players: Analysis by Number of Patents
10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography
10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Viral Vaccine
11.3.1. Global Demand for Scale of Operation
11.3.1.1. Clinical Demand for Viral Vaccine
11.3.1.2. Commercial Demand for Viral Vaccine
11.4.1. Geographical Analysis of Demand
11.4.1.1. Overall Demand in North America for Viral Vaccine
11.4.1.2. Overall Demand in Europe for Viral Vaccine
11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035
12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035
12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035
12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035
12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035
12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035
13. CONCLUSION
13.1. Chapter Overview
14. INTERVIEW TRANSCRIPT(S)15. APPENDIX I: TABULATED DATA16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Note: Product cover images may vary from those shown
  • 2BScientific
  • Adimmune
  • Aduro Biotech
  • Advagene Biopharma
  • Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
  • Advanced BioScience Laboratories
  • Advent
  • AJ Biologics
  • Albany Molecular Research
  • Alopexx Vaccine
  • Altimmune
  • Amphera
  • Anhui Zhifei Longcom Biologic Pharmacy
  • Applied Biosystems
  • Argos Therapeutics
  • Astellas Pharma
  • Asterias Biotherapeutics
  • ATZ labs
  • Auro Vaccines
  • Aurora Biopharma
  • AVAX Technologies
  • Avid Bioservices
  • AVIR Green Hills Biotechnology
  • Batavia Biosciences
  • Bavarian Nordic
  • BD Biosciences
  • Beijing Minhai Biotechnology
  • Beijing Zhifei Lvzhu Biopharmaceutical
  • Bharat Biotech
  • Bielefeld University
  • Bio Farma
  • BioCell
  • BioConnection
  • Biofabri
  • Biological E
  • Biological Industries
  • BioMARC
  • BioReliance
  • BlueWillow Biologics
  • Boehringer Ingelheim
  • Boryung Pharmaceutical
  • BravoVax
  • Bryllan
  • CanSino Biologics
  • Capricorn Scientific
  • Catalent Biologics
  • Cellca (Acquired by Sartorius)
  • CellGenix
  • CEVEC Pharmaceuticals
  • Charles River Laboratories
  • Chengdu Zenmindes Biotechnology
  • CiMaas
  • CJ HealthCare
  • Cobra Biologics
  • Codagenix
  • Commonwealth Serum Laboratories (CSL)
  • Creative Biolabs
  • Curevo Vaccine
  • Cytiva
  • CyTuVax
  • Daiichi Sankyo
  • DanDrit Biotech
  • DCPrime
  • Dendreon
  • Elios Therapeutics
  • Emergent BioSolutions
  • Fisher Scientific (Acquired by Thermo Fisher Scientific)
  • FluGen
  • FUJIFILM Wako Pure Chemicals
  • GC Pharma
  • GeneOne Life Science
  • GlaxoSmithKline
  • Gradalis
  • HALIX
  • Heat Biologics
  • Hilleman Laboratories
  • Hookipa Biotech
  • Icahn School of Medicine at Mount Sinai
  • IDT Biologika
  • ILiAD Biotechnologies
  • Immunicum
  • ImmunoCellular Therapeutics
  • Immutep
  • Indian Immunologicals
  • Inovio Pharmaceuticals
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Insud Pharma
  • Intermountain Life Sciences
  • Intervet
  • InVitria
  • Invitrogen
  • Irvine Scientific Sales (Acquired by FUJIFILM)
  • IS JAPAN (Acquired by FUJIFILM)
  • Janssen Pharmaceuticals
  • Jianshun Biosciences
  • JN International Medical
  • JW CreaGene
  • Kansas State University
  • KBI Biopharma
  • Kiromic
  • Leland Stanford Junior University
  • LG Chem
  • LimmaTech Biologics
  • Lonza
  • Luina Bio
  • Massachusetts Institute of Technology
  • MassBiologics
  • Medicago
  • Medigen Vaccine Biologics
  • Medigene
  • Meissa Vaccines
  • Merck
  • Meridian Life Science
  • MilliporeSigma
  • MinervaX
  • Moderna
  • MolecuVax
  • Northwest Biotherapeutics
  • Nova Immunotherapeutics
  • Novartis
  • Novasep
  • Novavax
  • NPO Petrovax Pharm
  • Ology Bioservices
  • Oncobiomed
  • OPM Biosciences
  • Osivax
  • Oxford Biomedica
  • Pall Corporation
  • Panacea Biotec
  • Patheon Viral Vector Services
  • PDC*line Pharma
  • Pfizer
  • Premas Biotech
  • Prestige BioPharma
  • ProBioGen
  • Regeneus
  • Research Institute at Nationwide Children's Hospital
  • Sanaria
  • Sanofi Pasteur
  • Saronic Biotechnology
  • Sartorius
  • Scandinavian Biopharma
  • Seqirus 
  • Serum Institute of India
  • Shanghai Bovax Biotechnology
  • Shenzhen Hornetcorn Biotechnology
  • Shenzhen Kangtai Biological Products
  • Sigma-Aldrich
  • SK Bioscience
  • SOTIO
  • Symbiosis Pharmaceutical Services
  • Takeda
  • TapImmune
  • Tella
  • Tessa Therapeutics
  • TeutoCell
  • Themis Bioscience
  • Thermo Electron
  • Thermo Fisher Scientific
  • Thousand Oaks Biopharmaceuticals
  • TNCbio
  • Unity Lab Services
  • University of California
  • University of Pennsylvania
  • University of Texas
  • USHEALTH
  • Vaccinogen
  • Vaccitech
  • Valneva
  • Vaxart
  • Vaxine
  • Vibalogics
  • Waisman Biomanufacturing
  • WuXi Biologics
  • Xell
  • XEME Biopharma
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...